Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Chemotherapy is a primary cancer treatment, but multidrug resistance (MDR) limits its effectiveness.
• Nanoparticles offer a promising strategy for overcoming MDR in cancer therapy.
• Mesoporous silica nanoparticles (MSNs) are widely used for drug delivery due to their porous structure.

Purpose of the Study:

• To review recent advancements in using MSNs for codelivering chemotherapeutic drugs and small interfering RNA (siRNA) for cancer treatment.
• To summarize synthesis and functionalization methods for MSNs in cancer therapy.
• To provide insights into nanoparticle-based combination therapy for improved chemotherapy outcomes.

Main Methods:

• Review of recent scientific literature on mesoporous silica nanoparticles for cancer therapy.
• Analysis of studies focusing on simultaneous delivery of chemotherapeutic agents and siRNA.
• Summary of MSN synthesis and surface modification techniques.

Main Results:

• MSNs enable efficient codelivery of chemotherapeutic drugs and siRNA, enhancing anticancer efficacy.
• Functionalization of MSNs can improve targeting and controlled release of therapeutic agents.
• Combination therapy using MSNs demonstrates potential to overcome multidrug resistance.

Conclusions:

• Mesoporous silica nanoparticles are effective carriers for codelivering chemotherapy and siRNA to combat cancer.
• Nanoparticle-based combination therapy represents a promising strategy to enhance cancer treatment outcomes.
• Further research into MSN synthesis and functionalization can optimize their clinical application in oncology.